

1 October 2024

Oxford Nanopore Technologies plc
Dr Daniel Mahony appointed as Non-Executive Director

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or "the Group"), the company delivering a new generation of nanopore-based molecular sensing technology, is pleased to announce that Dr Daniel Mahony will be joining the Group as a Non-Executive Director with effect from 1 October 2024.

Daniel brings extensive sector experience to help accelerate Oxford Nanopore's commercial traction, with more than 25 years as a global healthcare investor specialising in biotechnology, medical technology and healthcare services. As Senior Partner in Growth Investments at Novo Holdings, Daniel will serve as a critical sounding board to the Group as it continues to advance its technology platform to address a significant commercial opportunity in biopharmaceuticals. In addition, he currently chairs the UK BioIndustry Association and is a Non-Executive Director of the Wellcome Sanger Institute.

Prior to joining Novo Holdings, Daniel co-founded the healthcare business unit at Polar Capital in London, growing it to more than 4 billion in assets under management. He was formerly a Senior Research Analyst at Morgan Stanley in London, an Analyst at ING Barings Furman Selz in New York, and completed his postdoctoral work at DNAX Research Institute in Palo Alto.

Dr Guy Harmelin, a non-executive director of the Group, who has served on the Board since 2020, has informed the Board of his intention to step down from the Board with effect from today. Dr Guy Harmelin, is stepping down to focus on various other Directorship responsibilities.

Duncan Tatton-Brown, Chair of Oxford Nanopore, said: *"We are extremely pleased to welcome Daniel to the board as Non-Executive Director of Oxford Nanopore. Daniel's deep knowledge of the biopharma sector, combined with his understanding of Oxford Nanopore's opportunity to drive value across the biopharma development pipeline, position him as an ideal source of expertise to support the company's commercial expansion into this space. I would like to thank Guy, our outgoing non-executive director for his outstanding support overall and contribution in helping the Group transition from a private to a public company during his tenure."*

Dr Daniel Mahony, incoming Non-Executive Director of Oxford Nanopore, said: *"This is an exciting time for Oxford Nanopore with its expanding opportunity in biopharma, where rapid sequencing, richer data and a streamlined platform can support discovery and delivery of new biopharmaceuticals. I look forward to bringing my industry expertise to bear as Oxford Nanopore executes against its exciting growth plans in this sector."*

Dr Gordon Sanghera, Chief Executive Officer of Oxford Nanopore, said: *"Daniel brings substantial strategic experience to support Oxford Nanopore's commercial growth in the life sciences and specifically the biopharma market. His perspectives will be invaluable as we continue to expand the use of our technology to address the needs of this industry, and I look forward to working with Daniel as we enter this next phase. I also would like to thank Guy, our outgoing non-executive director, for his insight and guidance during his tenure on the board. We appreciate his significant contribution and wish him well in his next chapter."*

Novo Holdings is a shareholder in Oxford Nanopore and led the recent £80 million equity placing. The decision to appoint Dr Mahony to the Board of Oxford Nanopore reflects his considerable industry expertise and the value he brings to the Board.

This announcement is made pursuant to Listing Rule 9.6.11R. There are no other details required to be disclosed under Listing Rule 9.6.13R.

-ENDS-

For further information, please contact:

Oxford Nanopore Technologies plc

Investors: ir@nanoporetech.com

Media: media@nanoporetech.com

Teneo (communications adviser to the Group)

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.

For more information please visit: www.nanoporetech.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAEAXNEDDKLEFA